Picture of Enfusion logo

ENFN — Enfusion News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousMid CapHigh Flyer

Enfusion Inc expected to post earnings of 5 cents a share - Earnings Preview

* Enfusion Inc  ENFN.N   ENFN.K  is expected to show a rise
in
quarterly revenue when it reports  results on March 12 for the
period ending December 31 2023
    * The Chicago Illinois-based  company is expected to report
a
11.7% increase in revenue to $45.275 million from $40.52 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Enfusion Inc is for
earnings
of 5 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and 3 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Enfusion
Inc is
$9.88​, above​ its last closing price of $8.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.04        0.05       0.04      Missed  -12.5
 Jun. 30 2023  0.04        0.04       0.04      Met     -4.1
 Mar. 31 2023  0.03        0.03       0.02      Missed  -27.1​
 Dec. 31 2022  0.03        0.03       0.04      Beat    36.4
 ​​Sep.        0.01        0.02       0.03      Beat    50
 30 2022                                                
 Jun. 30 2022  0.02        0.02       0.04      Beat    100​
 Mar. 31 2022  0.03        0.03       0.00      Missed  -93.6
 Dec. 31 2021  0.03        0.04       0.02      Missed  -43.6
 This summary was machine generated March 8 at 13:17 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Enfusion

See all news